OBJECTIVE: Nifedipine is frequently used for acute tocolysis of preterm labor, despite there being no reports of its effectiveness compared to placebo. We sought to compare the effectiveness of nifedipine to placebo. STUDY DESIGN: We conducted a randomized, double-blind, placebocontrolled trial of nifedipine. Women ages 16-44 who had documented uterine activity and who were at risk of preterm birth were included if they had a singleton pregnancy with intact membranes between 28-0/7 and 33-6/7 weeks' gestation and cervical dilatation between 2 and 4 cm. Women who consented to participate were randomized and received nifedipine 20 mg or placebo orally, then nifedipine 20 mg or placebo orally after 90 minutes if still contracting. Nifedipine 20 mg or placebo was continued orally every 4 hours after the first dose, for 48 hours. RESULTS: The protocol specified that a total of 150 patients be included, but after a pre-planned interim analysis, the Data Safety Monitoring Committee recommended discontinuation of the trial due to futility. The study was terminated after randomization of a total of 88 subjects with data available for analysis: 46 for nifedipine and 42 for placebo. Nifedipine did not affect blood pressure in normotensive women, but heart rates were significantly increased after the first 4 hours and at the end of the 48-hour window. Despite this physiologic effect, there were no statistically significant differences in the primary or prespecified secondary outcomes (Table) . The rate of discontinuation for side effects did not differ. There were no stillbirths and no significant differences in neonatal outcomes. CONCLUSION: Acute tocolysis of preterm labor with nifedipine did not affect preterm birth rates, with the interim analysis demonstrating futility for study continuation.
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74 Delivery mode and future infectious morbidity of the offspring e a sibling analysis OBJECTIVE: Cesarean delivery (CD) has been shown to affect the newborn's microbiome, and was recently suggested to be associated with several long-term health implications in offspring. We aimed to investigate the association between delivery mode and long-term infectious morbidity of the offspring while employing sibling analysis theme in order to maximize confounder control. STUDY DESIGN: A prospectively analyzed population-based cohort study was performed, which included all sibling deliveries occurring between 1991 and 2014 at a regional tertiary medical center. The study included 13,516 individuals (6758 siblings pairs): the first born was via vaginal delivery (VD) and the second via CD. Each siblings pair was considered a matched set, with the aim to perform a withinfamily analysis. CD was considered the exposure, and VD the comparison. The risk for long-term infectious morbidity in offspring was based on the hospital's pediatric database and a pre-defined set of infectious ICD-9 code list associated with offspring hospitalizations. Only the first infectious related hospitalization for each child up to the age of 18 years was included. A KaplaneMeier survival curve was used to compare the cumulative infectious morbidity incidence and a Cox hazards models to control for confounders. RESULTS: Crude rates of total infectious hospitalizations were found to be significantly higher in the CD group (OR¼1.2; 95%CI, 1.12-1.4, p<0.001). Specifically, bronchiolitis (OR¼2.0, 95%CI 1.5-2.6, p<0.001), otitis (OR¼1.5, 95%CI 1.2-1.9, p<0.001), respiratory syncytial virus (OR¼4.3, 95%CI 1.2-15.2, p¼0.021) and gastroenteritis (OR¼1.4, 95%CI 1.1-1.9, p¼0.025; Table) were all found to be significantly more common in the CD group. The survival curve demonstrated significantly higher cumulative infectious related hospitalization rates in the CD group (log rank p<0.001; Figure) . The Cox model, adjusted for maternal age, birthweight, preeclampsia, diabetes, smoking, induction of labor, and obesity, confirmed the significant association between CD and later offspring infectious related morbidity (adjusted HR¼ 1.2; 95%CI 1.1-1.4, p¼0.027). CONCLUSION: CD appears to be independently associated with later offspring infectious related morbidity, even while rigorously adjusting for confounders. Physicians should consider potential 
